Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Cenovus Energy Inc (CVE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Cenovus Energy Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Cenovus Energy Inc trades at $26.79 (market cap $49.07B). The key difference: Cenovus Energy Inc is the larger of the two by market cap, and Cenovus Energy Inc pays a 2.35% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | CVE | |
|---|---|---|
Market Cap | $39.89B | $49.07B |
Sector | Health | Energy |
52-Week High | $491.22 | $31.80 |
52-Week Low | $278.09 | $13.96 |
Enterprise Value | $38.15B | $56.95B |
Dividend Yield | — | 2.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Cenovus Energy (CVE) trades at $26.40, up 1.62% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 14.93 and net income margin of 8.94%, supported by three consecutive quarterly earnings beats. Recent news highlights its 85% annual rally, driven by oil price gains and operational synergies from MEG Energy.
The outlook remains positive given its low-cost assets and integrated model, though risks include oil price volatility and execution of growth plans. Analyst consensus is mixed with 40.7% buy ratings, reflecting cautious optimism amid energy sector momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →
